All In Biotech

Drug Trial Radar · NCT01650779

A Study Evaluating Glycosphingolipid Clearance in Patients Treated With Agalsidase Alfa Who Switch to Agalsidase Beta

Evaluation of Glycosphingolipid Clearance in Patients Treated With Agalsidase Alfa Who Switch to Agalsidase Beta (The INFORM Study)

Last checked: Nov 20, 2026Latest source record: Jul 10, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

15

Actual

Start

Apr 2012

Primary completion

Mar 2013

Study completion Mar 2013

Sponsor

Lead sponsor
Genzyme, a Sanofi CompanySanofi (SNY)
Sponsor type
Industry
First posted
Jul 26, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
Male only
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an exploratory study to evaluate changes in glycosphingolipid levels and other (exploratory) Fabry disease parameters in male Fabry disease participants who were previously treated with agalsidase alfa (Replagal®) 0.2 milligram per kilogram (mg/kg) every two weeks (q2w) and who are being switched to agalsidase beta (Fabrazyme®) 1.0 mg/kg q2w.

Conditions

  • Fabry Disease

Interventions

  • Agalsidase betaBiological

    Commercially available agalsidase beta 1.0 mg/kg administered as an intravenous infusion q2w up to Month 6.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent Change From Baseline in Plasma Deacylated Globotriaosylceramide (Lyso-GL-3) at Month 2, 4 and 6Time frame: Baseline, Month 2, 4, 6

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • Site not named

    Coral Springs, Florida

  • Site not named

    Decatur, Georgia

  • Site not named

    Baltimore, Maryland

  • Site not named

    Grand Rapids, Michigan

  • Site not named

    Hellertown, Pennsylvania

  • Site not named

    Fairfax, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.